Tatyana M. Alekseeva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Interests
Tatyana M. Alekseeva has a total of 153 co-authors. Here are the top co-authors by number of shared publications:
- Mariya Petrovna Topuzova
Almazov National Medical Research Center
28 shared publications - Maria L. Pospelova
Federal State Budgetary Institution “V. A. Almazov National Medical Research Centre” of the Ministry of Health of the Russian Federation
13 shared publications - Ivan Konstantinovich Ternovykh
FSBI Almazov National Medical Research Center of the Ministry of Health of the Russian Federation, St. Petersburg, Russia
12 shared publications - Tat’yAna Alekseevna Shustova
Almazov National Medical Research Center
9 shared publications - Valeriya A. Malko
Almazov National Medical Research Center
9 shared publications - Gennady Nikolaevich Bisaga
Almazov National Medical Research Center
8 shared publications
Latest Publications
- Open Access
- 18 August 2026
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 18 (4) , 122-127
A personalized approach to the treatment of generalized myasthenia gravis
Generalized myasthenia gravis is a chronic autoimmune disorder characterized by an attack on the structures of the neuromuscular junction and by fluctuating muscle weakness and pathological fatigue, involving the ocular, bulbar, respiratory and skeletal muscles. Modern treatment of generalized myasthenia gravis aims to achieve sustained control of the disease, reduce the risk of exacerbations and myasthenic crises, and maintain the patient's quality of life. Some patients continue to experience a significant burden of disease, reduced daily activity, a need for longterm immunosuppressive therapy, and a risk of developing adverse events. A personalized approach to the treatment of generalized myasthenia gravis should take into account serological status, disease activity, the frequency of exacerbations, comorbidities, tolerance to treatment, the possibility of reducing the dose of glucocorticoids, and the patient's preferences.
- 18 August 2026
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 18 (4) , 122-127
Open AccessA personalized approach to the treatment of generalized myasthenia gravis
Generalized myasthenia gravis is a chronic autoimmune disorder characterized by an attack on the structures of the neuromuscular junction and by fluctuating muscle weakness and pathological fatigue, involving the ocular, bulbar, respiratory and skeletal muscles. Modern treatment of generalized myasthenia gravis aims to achieve sustained control of the disease, reduce the risk of exacerbations and myasthenic crises, and maintain the patient's quality of life. Some patients continue to experience a significant burden of disease, reduced daily activity, a need for longterm immunosuppressive therapy, and a risk of developing adverse events. A personalized approach to the treatment of generalized myasthenia gravis should take into account serological status, disease activity, the frequency of exacerbations, comorbidities, tolerance to treatment, the possibility of reducing the dose of glucocorticoids, and the patient's preferences.
- 7 August 2026
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 126 (7) , 133-137
Results of the scientific and practical conference with international participation «Neurology of the XXI Century: Current Issues, Achievements and Innovations». March 26—27, 2026, St. Petersburg
This article presents the findings from the fifth scientific and practical conference with international participation entitled «Neurology of the XXI Century: Current Issues, Achievements and Innovations,» held on March 26—27, 2026, in St. Petersburg. The scientific program included plenary sessions, sectional reports, master classes, educational events, and clinical cases presented by participants from both Russia and abroad. The conference attracted over 1.000 specialists. Key topics discussed included vascular pathology of the brain, neurodegenerative diseases, immune-mediated neuromuscular disorders, multiple sclerosis, epilepsy, neuroinfections, pain syndromes, and medical rehabilitation. Special emphasis was placed on the importance of interdisciplinary approaches and personalized medicine. The conference not only highlighted a high standard of scientific and educational engagement but also fostered professional exchange of experiences and pinpointed promising directions for advancing neurology. The next conference is scheduled for spring 2027.
- 7 August 2026
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 126 (7) , 133-137
Results of the scientific and practical conference with international participation «Neurology of the XXI Century: Current Issues, Achievements and Innovations». March 26—27, 2026, St. Petersburg
This article presents the findings from the fifth scientific and practical conference with international participation entitled «Neurology of the XXI Century: Current Issues, Achievements and Innovations,» held on March 26—27, 2026, in St. Petersburg. The scientific program included plenary sessions, sectional reports, master classes, educational events, and clinical cases presented by participants from both Russia and abroad. The conference attracted over 1.000 specialists. Key topics discussed included vascular pathology of the brain, neurodegenerative diseases, immune-mediated neuromuscular disorders, multiple sclerosis, epilepsy, neuroinfections, pain syndromes, and medical rehabilitation. Special emphasis was placed on the importance of interdisciplinary approaches and personalized medicine. The conference not only highlighted a high standard of scientific and educational engagement but also fostered professional exchange of experiences and pinpointed promising directions for advancing neurology. The next conference is scheduled for spring 2027.
- 30 April 2026
- Published by PANORAMA Publishing House in Vestnik Nevrologii, Psihiatrii i Nejrohirurgii (Bulletin of Neurology, Psychiatry and Neurosurgery)
- No. 4,p. 629-639
Structural characteristics of night sleep and dynamics of impaired functions recovery in patients after ischemic stroke
In addition to immediate focal neurological impairments, patients often experience significant mood swings, fatigue, and sleep disturbances during recovery from ischemic stroke. If left unnoticed and not promptly addressed, these conditions can negatively impact neuroplasticity, which is essential for restoring impaired functions. The purpose of this study was to evaluate the impact of disrupted nocturnal sleep patterns on the dynamics of motor, cognitive, and affective impairments in patients who have suffered ischemic stroke. The study included 115 patients after ischemic stroke. In patients in the acute period of ischemic stroke, the highest apnea-hypopnea index was detected (27.00 [14.55; 38.80] episodes/hour, p<0.05), while insomnia disorders predominated in the early and late recovery periods, expressed in a decrease in sleep efficiency to 46-50% (with the norm of 70%) and an increase in the time of falling asleep. A higher apnea-hypopnea index was associated with a slower regression of anxiety manifestations (ρ=-0.356, p=0.008). At the same time, higher sleep efficiency and the presence of deep slow sleep were associated with better recovery of mobility and a decrease in the level of anxiety in patients, respectively. This study demonstrates that the nature of sleep disorders in patients after ischemic stroke regularly changes depending on the period of the disease. This highlights the importance of targeted sleep assessment at all stages of rehabilitation and points to potential therapeutic targets for optimizing the recovery of neurological and emotional functions.
- 30 April 2026
- Published by PANORAMA Publishing House in Vestnik Nevrologii, Psihiatrii i Nejrohirurgii (Bulletin of Neurology, Psychiatry and Neurosurgery)
- No. 4,p. 629-639
Structural characteristics of night sleep and dynamics of impaired functions recovery in patients after ischemic stroke
In addition to immediate focal neurological impairments, patients often experience significant mood swings, fatigue, and sleep disturbances during recovery from ischemic stroke. If left unnoticed and not promptly addressed, these conditions can negatively impact neuroplasticity, which is essential for restoring impaired functions. The purpose of this study was to evaluate the impact of disrupted nocturnal sleep patterns on the dynamics of motor, cognitive, and affective impairments in patients who have suffered ischemic stroke. The study included 115 patients after ischemic stroke. In patients in the acute period of ischemic stroke, the highest apnea-hypopnea index was detected (27.00 [14.55; 38.80] episodes/hour, p<0.05), while insomnia disorders predominated in the early and late recovery periods, expressed in a decrease in sleep efficiency to 46-50% (with the norm of 70%) and an increase in the time of falling asleep. A higher apnea-hypopnea index was associated with a slower regression of anxiety manifestations (ρ=-0.356, p=0.008). At the same time, higher sleep efficiency and the presence of deep slow sleep were associated with better recovery of mobility and a decrease in the level of anxiety in patients, respectively. This study demonstrates that the nature of sleep disorders in patients after ischemic stroke regularly changes depending on the period of the disease. This highlights the importance of targeted sleep assessment at all stages of rehabilitation and points to potential therapeutic targets for optimizing the recovery of neurological and emotional functions.
- Open Access
- 23 September 2025
- Published by Publishing House ABV Press in Neuromuscular Diseases
- Vol. 15 (2) , 37-47
Factors influencing the progression of amyotrophic lateral sclerosis: prospective cohort study
Aim. Using factor analysis, identify and rank the parameters potentially influencing the course of amyotrophic lateral sclerosis (ALS) according to their significance.Materials and methods. A prospective cohort study of 70 patients with ALS diagnosed according to the Gold Coast criteria (2020) was performed. We studied basic socio-demographic indicators, education and social status, geography of living, anamnestic data about the disease (appearance of the first symptoms, onset, etc.), clinical picture (symptoms in the main muscle groups), progression of ALSFRS-R score, environmental risk factors (including 23 features, presented in gradation from the lowest to the highest expression).Results. The mean age of the patients was 60.62 ± 10.2 years. The predominant proportion of patients was female,61.4 % (n = 43), the proportion of males was 38.6 % (n = 27). The mean time from onset of symptoms to inclusion in the study and questionnaire was 12 months (95 % confidence interval 9.00–21.50). Low level of education, onset from bulbar symptoms and neck muscle involvement, severity of oral automatism reflexes, difficulty in walking and standing, contact with heavy metals, occupational sports and high stress level were correlated with rapid progression of ALS, while high level of physical activity, frequent caffeine consumption, antioxidant intake, vitamin D deficiency were observed in slow progression of ALS.Conclusion. Our data confirm that ALS is a clinically and pathogenetically heterogeneous disease, whose rate of progression is influenced by a wide range of clinical, anamnestic, and environmental factors.
- 23 September 2025
- Published by Publishing House ABV Press in Neuromuscular Diseases
- Vol. 15 (2) , 37-47
Open AccessFactors influencing the progression of amyotrophic lateral sclerosis: prospective cohort study
Aim. Using factor analysis, identify and rank the parameters potentially influencing the course of amyotrophic lateral sclerosis (ALS) according to their significance.Materials and methods. A prospective cohort study of 70 patients with ALS diagnosed according to the Gold Coast criteria (2020) was performed. We studied basic socio-demographic indicators, education and social status, geography of living, anamnestic data about the disease (appearance of the first symptoms, onset, etc.), clinical picture (symptoms in the main muscle groups), progression of ALSFRS-R score, environmental risk factors (including 23 features, presented in gradation from the lowest to the highest expression).Results. The mean age of the patients was 60.62 ± 10.2 years. The predominant proportion of patients was female,61.4 % (n = 43), the proportion of males was 38.6 % (n = 27). The mean time from onset of symptoms to inclusion in the study and questionnaire was 12 months (95 % confidence interval 9.00–21.50). Low level of education, onset from bulbar symptoms and neck muscle involvement, severity of oral automatism reflexes, difficulty in walking and standing, contact with heavy metals, occupational sports and high stress level were correlated with rapid progression of ALS, while high level of physical activity, frequent caffeine consumption, antioxidant intake, vitamin D deficiency were observed in slow progression of ALS.Conclusion. Our data confirm that ALS is a clinically and pathogenetically heterogeneous disease, whose rate of progression is influenced by a wide range of clinical, anamnestic, and environmental factors.
- Open Access
- 22 September 2025
- Published by Federal State Budgetary Institution "National Medical Research Center named after. V.A. Almazov" Ministry of Health of the Russian Federation" in Russian Neurosurgical Journal named after Professor A. L. Polenov
- Vol. 17 (2) , 72-80
Neurocognitive and neuroimaging markers of central nervous system damage in patients with the cerebral variant of postmastectomy syndrome
INTRODUCTION. Breast cancer is the leading oncological pathology in the female population. Active treatment, including surgery, chemo and radiation therapy, forms a set of disorders. Such complex of disorders is called postmastectomy syndrome. One of the neurological manifestations is the cerebral variant, characterized by impaired memory, attention, a feeling of “unclear” head, in some cases the development of fainting, balance disorders, strokes. Such manifestations reduce the quality of life and require early diagnosis and adequate correction. AIM. Assessment of the brain condition of patients with cerebral manifestations of postmastectomy syndrome using a battery of neurocognitive tests and magnetic resonance morphometry MATERIALS AND METHODS. An open single-center controlled trial was conducted with 86 patients with postmastectomy syndrome and 28 healthy female volunteers. A comprehensive assessment of the patients’ condition was carried out: neurological examination, neurocognitive testing, magnetic resonance morphometry. RESULTS. In women with postmastectomy syndrome, there was a statistically significant decrease in the speed of neurocognitive tests, as well as a decrease in the number of correct answers compared with the group of healthy volunteers. There was also a decrease in the volume of such brain structures as the cerebral cortex, cerebellar cortex, frontal, occipital, parietal lobes, thalamuses, and precentral gyri. CONCLUSION. In patients with the cerebral variant of postmastectomy syndrome, clinical and instrumental signs of damage to the central nervous system are determined. Good survival rates, as well as the high prevalence of neurological manifestations, create the need to create effective and accessible diagnostic strategies, as well as adequate and timely treatment.
- 22 September 2025
- Published by Federal State Budgetary Institution "National Medical Research Center named after. V.A. Almazov" Ministry of Health of the Russian Federation" in Russian Neurosurgical Journal named after Professor A. L. Polenov
- Vol. 17 (2) , 72-80
Open AccessNeurocognitive and neuroimaging markers of central nervous system damage in patients with the cerebral variant of postmastectomy syndrome
INTRODUCTION. Breast cancer is the leading oncological pathology in the female population. Active treatment, including surgery, chemo and radiation therapy, forms a set of disorders. Such complex of disorders is called postmastectomy syndrome. One of the neurological manifestations is the cerebral variant, characterized by impaired memory, attention, a feeling of “unclear” head, in some cases the development of fainting, balance disorders, strokes. Such manifestations reduce the quality of life and require early diagnosis and adequate correction. AIM. Assessment of the brain condition of patients with cerebral manifestations of postmastectomy syndrome using a battery of neurocognitive tests and magnetic resonance morphometry MATERIALS AND METHODS. An open single-center controlled trial was conducted with 86 patients with postmastectomy syndrome and 28 healthy female volunteers. A comprehensive assessment of the patients’ condition was carried out: neurological examination, neurocognitive testing, magnetic resonance morphometry. RESULTS. In women with postmastectomy syndrome, there was a statistically significant decrease in the speed of neurocognitive tests, as well as a decrease in the number of correct answers compared with the group of healthy volunteers. There was also a decrease in the volume of such brain structures as the cerebral cortex, cerebellar cortex, frontal, occipital, parietal lobes, thalamuses, and precentral gyri. CONCLUSION. In patients with the cerebral variant of postmastectomy syndrome, clinical and instrumental signs of damage to the central nervous system are determined. Good survival rates, as well as the high prevalence of neurological manifestations, create the need to create effective and accessible diagnostic strategies, as well as adequate and timely treatment.
- 8 August 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (7) , 66-72
Study of neurodegeneration in multiple sclerosis using optical coherence tomography of the retina and magnetic resonance morphometry of the brain
Objective. To search and study the relationship between the change in the thickness of the retinal ganglionic complex layers and the volumetric indicators of the brain in patients with multiple sclerosis (MS). Materials and methods. Fifty-seven MS patients aged 19 to 68 years (mean age 39.6±11.2 years) were examined with a diagnosis confirmed by the 2017 McDonald criteria and no previous history of optic neuritis. All patients underwent MRI brain morphometry, optical coherence tomography (OCT) of the retina, and an Expand Disability Status Scale (EDSS) assessment. Results. A direct correlation was found between the thickness of most layers of the “internal” retina and the total volume of white and gray matter of the telencephalon, nuclei accumbens, pallidum, ventral diencephalon, superior parietal gyrus, thalamus, and inversely with the size of the ventricular system of the brain, subcallosal zone, total volume of cerebrospinal fluid (CSF), and foci of brain lesion. The transverse size of the ganglion cell layer (GCL) correlated most with the volumetric parameters of the brain: with the volumes of gray (r=0.426; p=0.001) and white (r=0.564; p<0.000) matter, the nucleus accumbens (r=0.841; p<0.000), thalamus (r=0.542; p=0.000), CSF (r=–0.601; p<0.000), and cingulate gyrus (r=0.304; p=0.002). A less distinct correlation was found between the brain parameters and the thickness of the ganglion cell layer and the inner plexiform layer (GCIPL) with volumes of gray (r=0.389; p=0.002) and white (r=0.439; p=0.000) matter, nucleus accumbens (r=0.463; p=0.000), thalamus (r=0.447; p=0.000), CSF (r=–0.518; p<0.000), cerebellum (r=0.331; p=0.012), and peripapillary retinal nerve fiber layer (pRNFL) with volumes of white matter (r=0.419; p=0.001), nucleus accumbens (r=0.421; p=0.001), thalamus (r=0.396; p=0.002), CSF (r=–0.368; p=0.004), and hippocampus (r=0.399; p=0.002). A significant positive correlation was found between the thickness of the macular retinal nerve fiber layer (mRNFL) and cerebellar volumetric parameters (r=0.351; p=0.007). Conclusion. The anatomical and pathological structure of the eye’s retina reflects the neurodegeneration of the central nervous system as a whole. The most sensitive markers of regional gray matter atrophy of the brain are macular thickness in GCL and GCIPL, as well as pRNFL.
- 8 August 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (7) , 66-72
Study of neurodegeneration in multiple sclerosis using optical coherence tomography of the retina and magnetic resonance morphometry of the brain
Objective. To search and study the relationship between the change in the thickness of the retinal ganglionic complex layers and the volumetric indicators of the brain in patients with multiple sclerosis (MS). Materials and methods. Fifty-seven MS patients aged 19 to 68 years (mean age 39.6±11.2 years) were examined with a diagnosis confirmed by the 2017 McDonald criteria and no previous history of optic neuritis. All patients underwent MRI brain morphometry, optical coherence tomography (OCT) of the retina, and an Expand Disability Status Scale (EDSS) assessment. Results. A direct correlation was found between the thickness of most layers of the “internal” retina and the total volume of white and gray matter of the telencephalon, nuclei accumbens, pallidum, ventral diencephalon, superior parietal gyrus, thalamus, and inversely with the size of the ventricular system of the brain, subcallosal zone, total volume of cerebrospinal fluid (CSF), and foci of brain lesion. The transverse size of the ganglion cell layer (GCL) correlated most with the volumetric parameters of the brain: with the volumes of gray (r=0.426; p=0.001) and white (r=0.564; p<0.000) matter, the nucleus accumbens (r=0.841; p<0.000), thalamus (r=0.542; p=0.000), CSF (r=–0.601; p<0.000), and cingulate gyrus (r=0.304; p=0.002). A less distinct correlation was found between the brain parameters and the thickness of the ganglion cell layer and the inner plexiform layer (GCIPL) with volumes of gray (r=0.389; p=0.002) and white (r=0.439; p=0.000) matter, nucleus accumbens (r=0.463; p=0.000), thalamus (r=0.447; p=0.000), CSF (r=–0.518; p<0.000), cerebellum (r=0.331; p=0.012), and peripapillary retinal nerve fiber layer (pRNFL) with volumes of white matter (r=0.419; p=0.001), nucleus accumbens (r=0.421; p=0.001), thalamus (r=0.396; p=0.002), CSF (r=–0.368; p=0.004), and hippocampus (r=0.399; p=0.002). A significant positive correlation was found between the thickness of the macular retinal nerve fiber layer (mRNFL) and cerebellar volumetric parameters (r=0.351; p=0.007). Conclusion. The anatomical and pathological structure of the eye’s retina reflects the neurodegeneration of the central nervous system as a whole. The most sensitive markers of regional gray matter atrophy of the brain are macular thickness in GCL and GCIPL, as well as pRNFL.
- 26 July 2025
- Published by Alfmed LLC in Medical alphabet
- No. 15,p. 26-30
Postcovid cognitive decline, its risk factors and diagnostic biomarkers
Cognitive impairment (CI) is one of the main symptoms of both the acute period of COVID-19 and post-COVID syndrome, manifested by memory, attention and executive functions decline, which may persist or worsen months after infection. Risk factors for developing postcovid CI (PCI) include old age, female gender, low educational and socio-economic status, prolonged social isolation, severe COVID-19, use of certain medications, and concomitant diseases such as dementia and cardiovascular diseases. Vaccination against COVID-19 is considered as an effective way to prevent PCI. Diagnosis of PCI is based on the study of biomarkers in blood and cerebrospinal fluid (CSF), neuroimaging and neurophysiological data. Studies have revealed a link between cognitive impairment and the presence of antineuronal antibodies in the blood and CSF, structural changes in the brain (decrease in gray matter thickness and tissue damage in memory and attention areas), decreased glucose metabolism in key areas of the brain (according to PET scans) and abnormalities in brain electrical activity (according to EEG data). PCI is a serious problem for global health, exacerbated by the COVID-19 pandemic, which requires a comprehensive approach to the study, diagnosis, treatment and rehabilitation of patients.
- 26 July 2025
- Published by Alfmed LLC in Medical alphabet
- No. 15,p. 26-30
Postcovid cognitive decline, its risk factors and diagnostic biomarkers
Cognitive impairment (CI) is one of the main symptoms of both the acute period of COVID-19 and post-COVID syndrome, manifested by memory, attention and executive functions decline, which may persist or worsen months after infection. Risk factors for developing postcovid CI (PCI) include old age, female gender, low educational and socio-economic status, prolonged social isolation, severe COVID-19, use of certain medications, and concomitant diseases such as dementia and cardiovascular diseases. Vaccination against COVID-19 is considered as an effective way to prevent PCI. Diagnosis of PCI is based on the study of biomarkers in blood and cerebrospinal fluid (CSF), neuroimaging and neurophysiological data. Studies have revealed a link between cognitive impairment and the presence of antineuronal antibodies in the blood and CSF, structural changes in the brain (decrease in gray matter thickness and tissue damage in memory and attention areas), decreased glucose metabolism in key areas of the brain (according to PET scans) and abnormalities in brain electrical activity (according to EEG data). PCI is a serious problem for global health, exacerbated by the COVID-19 pandemic, which requires a comprehensive approach to the study, diagnosis, treatment and rehabilitation of patients.
- 3 June 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (5) , 125-130
Phenotypic heterogeneity of Charcot–Marie–Tooth type 2A disease associated with the c.1091G>C missense mutation (p.Arg364Pro) in the MFN2 gene
Charcot–Marie–Tooth disease belongs to the group of genetically and phenotypically heterogeneous sensory-motor polyneuropathies. Charcot–Marie–Tooth disease type 2A (CMT2A) is the most common axonal form of the disease caused by mutations in the mitofusin-2 gene (MFN2). More than 100 missense mutations in this gene have been registered to date. Many studies have demonstrated the variability of clinical presentation depending on the specific localization of the substitution. The presented clinical case shows the peculiarities of the phenotype of a patient with CMT2A disease associated with the c.1091G>C (p.Arg364Pro) missense mutation in the MFN2 gene.
- 3 June 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (5) , 125-130
Phenotypic heterogeneity of Charcot–Marie–Tooth type 2A disease associated with the c.1091G>C missense mutation (p.Arg364Pro) in the MFN2 gene
Charcot–Marie–Tooth disease belongs to the group of genetically and phenotypically heterogeneous sensory-motor polyneuropathies. Charcot–Marie–Tooth disease type 2A (CMT2A) is the most common axonal form of the disease caused by mutations in the mitofusin-2 gene (MFN2). More than 100 missense mutations in this gene have been registered to date. Many studies have demonstrated the variability of clinical presentation depending on the specific localization of the substitution. The presented clinical case shows the peculiarities of the phenotype of a patient with CMT2A disease associated with the c.1091G>C (p.Arg364Pro) missense mutation in the MFN2 gene.
- Open Access
- 29 May 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (11) , 5240
Amyotrophic Lateral Sclerosis: Pathophysiological Mechanisms and Treatment Strategies (Part 2)
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease associated with damage to motor neurons and leading to severe muscle weakness and, eventually, death. Over the past decade, understanding of the key pathogenetic links of ALS, including glutamate-mediated excitotoxicity and oxidative stress, has significantly advanced. This review considers the recent evidence on molecular mechanisms of these processes, as well as the therapeutic strategies aimed at their modulation. Special attention is paid to antiglutamatergic and antioxidant drugs as approaches to the ALS pathogenetic therapy.
- 29 May 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (11) , 5240
Open AccessAmyotrophic Lateral Sclerosis: Pathophysiological Mechanisms and Treatment Strategies (Part 2)
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease associated with damage to motor neurons and leading to severe muscle weakness and, eventually, death. Over the past decade, understanding of the key pathogenetic links of ALS, including glutamate-mediated excitotoxicity and oxidative stress, has significantly advanced. This review considers the recent evidence on molecular mechanisms of these processes, as well as the therapeutic strategies aimed at their modulation. Special attention is paid to antiglutamatergic and antioxidant drugs as approaches to the ALS pathogenetic therapy.
- 12 May 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (4) , 108-113
Challenges of differential diagnosis in the verification of Behçet’s disease with neurological manifestations
Behçet’s disease (BD) is an autoimmune vasculitis of unclear etiology characterized by a wide range of systemic manifestations. The nervous system is involved in approximately 10% of patients with BD (neuro-Behçet). Diagnosis of neuro-Behçet is challenging, especially in the case of BD onset with neurological manifestations, and is based on a combination of clinical, laboratory, and neuroimaging data. To verify the diagnosis of neuro-Behçet, a wide range of conditions with similar manifestations must be ruled out: multiple sclerosis, neuromyelitis optica spectrum disorder, neurosarcoidosis, and many rare autoimmune diseases (e.g., Cogan syndrome, Susac syndrome, Vogt-Koyanagi-Harada syndrome). This article presents a brief literature review highlighting the challenges of neuro-Behçet differential diagnosis and a clinical case of a 34-year-old male patient with a criteria-based diagnosis of BD with neurological manifestations.
- 12 May 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (4) , 108-113
Challenges of differential diagnosis in the verification of Behçet’s disease with neurological manifestations
Behçet’s disease (BD) is an autoimmune vasculitis of unclear etiology characterized by a wide range of systemic manifestations. The nervous system is involved in approximately 10% of patients with BD (neuro-Behçet). Diagnosis of neuro-Behçet is challenging, especially in the case of BD onset with neurological manifestations, and is based on a combination of clinical, laboratory, and neuroimaging data. To verify the diagnosis of neuro-Behçet, a wide range of conditions with similar manifestations must be ruled out: multiple sclerosis, neuromyelitis optica spectrum disorder, neurosarcoidosis, and many rare autoimmune diseases (e.g., Cogan syndrome, Susac syndrome, Vogt-Koyanagi-Harada syndrome). This article presents a brief literature review highlighting the challenges of neuro-Behçet differential diagnosis and a clinical case of a 34-year-old male patient with a criteria-based diagnosis of BD with neurological manifestations.